Medindia

X

Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis

Wednesday, December 9, 2009 Corporate News J E 4
Advertisement


NEW YORK, Dec. 8 Reportlinker.com announces that a new market research report is available in its catalogue:

Radiopharmaceuticals - A US and European Market Analysis

http://www.reportlinker.com/p0164273/Radiopharmaceuticals---A-US-and-European-Market-Analysis.html

The market for radiopharmaceuticals continues to gain momentum with heightened interest in therapeutic efficiency, acceptance and utilization of nuclear medicine equipment, as well as development of newer diagnostic and therapeutic agents. Besides oncology applications, the nuclear medicine field is presently exploring the possibility of extending the scope and functionality of radiopharmaceuticals to other disease applications such as infection imaging, nephrology and neurology applications. Advancements in nuclear medicine technology would represent a key strategic factor in opening up new clinical opportunities for radiopharmaceutical agents.

These and other market data and trends are presented in "Radiopharmaceuticals: A US and European Market Analysis" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

RADIOPHARMACEUTICALS BMR-1073

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. GLOBAL MARKET OVERVIEW 3

A Quick Primer 3

Key Market Trends 4

Continuous Battle Against Cancer: A Key Driver for Growth 4

Cancer Statistics: A Grim Prognosis 4

Business Case for Radiopharmaceuticals Exemplified 4

Development of Newer Diagnostic Agents to Boost Growth 5

Demographics & New Applications Offer Opportunities On a Platter 5

Recognition of Intrinsic Cost Benefits: Critical to Market

Acceptance 5

Widespread Awareness Among Practitioners & Patients: The Need

of the Hour 6

Expansion of Molecular Imaging Platform is Key to Future Growth 6

Molecular Imaging Agents: A Noteworthy Breakthrough 7

Growing Demand for PET to Drive Up Demand 7

Introduction of SPECT/CT & PET/CT: Double Edged Weapons for

Growth 8

Manufacturers Quick to Take Cue 8

Promising Developments in Therapeutic Radiopharmaceuticals

Underway 9

Targeted Peptides & Alpha Emitters: The New Frontiers of

Therapeutic Radiopharmaceuticals 9

International Collaborations Give a Thumbs Up to Drug

Development 10

Market Challenges 10

High Costs of Drug Development Piques Manufacturers 10

Supply Shortages: A Niggling Cause of Concern 10

Price Sensitivity & Competition from Alternatives Limit

Market Potential 11

Lack of Dosage Standards for Pediatric Patients' Limits

Radiopharmaceutical Efficacy 11

Unfounded Fears of Radiation Exposure Hinder Growth 12

Bottlenecks in Developing Markets 12

Market Share Statistics: In Retrospect 12

3. PRODUCT FACTS 13

A. Diagnostic Radiopharmaceuticals 13

B. Therapeutic Radiopharmaceuticals 14

4. REGIONAL MARKET OVERVIEW 15

i. The United States 15

ii. Europe 34

ii(a). France 37

ii(b). Germany 38

ii(c). Italy 39

ii(d). The United Kingdom 40

ii(e). Spain 41

ii(f). Rest of Europe 42

5. RESEARCH & DEVELOPMENT BREAKTHROUGHS 44

Azaya, Texas University Collaborate for Liposomal Radiation

Therapy 44

Pharmacyclics Reveals Phase 1/2 Study of MGd Antibody Targeted

Radiation Therapy 44

Peregrine Explores Potential of Cotara® for Brain Cancer

Treatment 44

Scientists Develop New Manufacturing Technology For Cancer

Diagnostic Radioisotopes 45

Avid Radiopharmaceuticals Exploits ExpIND to Speed AD Drug

Research 45

Scientists Commend Combination Therapy for Follicular Lymphoma

Patients 46

Missouri University Develops New Cancer Radiotherapy Method 46

AGH Researchers Develop New Radioactive Seed Therapy for Lung

Cancer 47

AnazaoHealth® Obtains US Patent for Novel Radiopharmaceutical

Preparations 47

INMAS Develops Ciprofloxacin Radiolabelling Kit 47

6. CORPORATE DEVELOPMENTS 48

Positron Concludes Dose Shield Acquisition 48

Positron Licenses NuView to Sell Imaging Technologies and Dose

Dispensing Devices 48

Bracco Imaging, Marillion Pharmaceuticals to Develop Novel

Cancer Treatment 48

EUSA Pharma Concludes Cytogen Acquisition 48

AMIC, CRS to Co-Produce Indium-111 49

AMIC, MU Partner to Produce Radioisotopes 49

Bracco, Lantheus to Co-Promote CardioGen-82® 49

Cell Therapeutics Submits sBLA for Use of Zevalin® in First-

Line Therapy 49

Covidien Gets FDA Nod for Generic Myocardial Perfusion Imaging

Kit 49

GE Healthcare Gets FDA Nod For New PET/CT Scanner 50

GE Healthcare, Gamma Medica-Ideas Ink Distribution Deal 50

CIS-US Receives FDA Approval for Generic Choletec® Kit 50

Cellectar Obtains Funds for Clinical Trials 50

Lantheus Medical Completes Phase I Study of Novel PET Imaging

Tracer 50

GE Healthcare, Cardinal Health Partner for Myoview(TM) Imaging Agent 51

Avista Capital Partners Acquires Medical Imaging Unit of

Bristol-Myers 51

Siemens Healthcare Opens Two Radiopharmacies in US 51

Cardinal Health Plans to Offer Services to Support PET

Clinical Trials 51

MEDRAD Associates with PETNET to Ingeniously Deliver FDG 52

Triad Isotopes to Build Four Nuclear Pharmacies 52

AREVA, NCI to Develop Cancer-fighting Radiopharmaceuticals 52

Cardinal Health Expands Manufacturing Capabilities for PET

Imaging Agents 52

Jubilant Completes Draxis Acquisition 53

IBA Plans to Acquire CIS BIO 53

Ion Beam Announces Closure of TAEK Financing 53

IBA Receives Approval for New Radiopharmaceutical Production

Facility in UK 54

Ion Beam Partners with Lantheus to Distribute Neurolite®,

Cardiolite® in Europe 54

EIS Eczacibasi to Acquire 50 Percent Stake in Monrol 54

Siemens to Set up Multiple Radiopharmaceutical Facilities in

India 54

Siemens Plans to Establish Its First Molecular Imaging Centre

in India 55

Bayer and FutureChem Enter Radiolabeling Technology Licensing

Agreement 55

Medrad Mounts Intego(TM) PET Infusion System at UPMC 55

IBA Molecular Announces the Launch of Cyclone ® 18 Twin 56

Immunomedics Announces Pre-Clinical Results for its

Combination Radioimmunotherapy 56

Molecular Insight Develops New Radioiodinated Molecules 56

Immunomedics Develops New Antibody for Radioimmunotherapy 56

Triad Acquires Four Radiopharmaceutical Companies 57

Triad Isotopes Acquires Regional Nuclear Pharmacies 57

Triad Isotopes Merges with Diversified Pharmacy Group 57

Molecular Insight Pharmaceuticals Acquires Radiopharmaceutical

Facility In Texas 57

GE Healthcare to Shelf Production of Products with Short-Lived

Radioisotopes 57

Cell Therapeutics Acquires Zevalin® Lymphoma Drug 57

Premier Signs Contracts with Mallinckrodt, Agfa, Berlex 58

ADMD Announces Patent Licensing for Preparing Actinium-225 58

Bayer Schering Exercises Rights to License Avid's 18-F AV1/ZK

Compound 58

Covidien Signs Agreement with BioSynthema for Cancer Treatment

Technology 59

IBA Signs Contract to Supply Cyclone® 30 to Indian DAE 59

MDS Nordion, Ottawa University to Establish Molecular Imaging

Center of Excellence 59

Bracco, ImaRx Ink Cross Licensing Deal 60

GE Healthcare Signs Exclusive Distribution Deal with Draximage 60

DRAXIMAGE, Med Discovery Form Research Collaboration 60

Schering Changes Corporate Identity to Bayer Schering Pharma AG 60

IBA Establishes New Radiopharmaceuticals Production Facility 61

IBA Receives Approval for Production of Radiopharmaceuticals

at UK Facility 61

IBA Establishes Production and R&D Center in Belgium 61

MDS Nordion to Expand Medical Imaging Agent Production in Europe 61

MDS Nordion, Avid Radiopharmaceuticals Ink Collaborative

Agreement 62

MDS Nordion Establishes Centers of Excellence for TheraSphere®

in Europe 62

Peregrine Opens Facility in China 62

GE Healthcare Receives Approval for First Radiopharmacy

Facility in India 62

Peregrine Pharmaceuticals Launches Anti-Cancer Agent in China 63

GE Healthcare Introduces Proton Package For Radiation Therapy

Planning 63

GE Healthcare Expands Definium Series of Digital Radiographic

Products 63

7. MAJOR PLAYERS 64

Actinium Pharmaceuticals, Inc. (US) 64

Advanced Medical Isotope Corporation (US) 64

Alseres Pharmaceuticals, Inc (US) 64

Bayer HealthCare Pharmaceuticals (US) 64

Bio-Nucleonics, Inc. (US) 64

Bracco Diagnostics, Inc. (US) 65

Cardinal Health, Inc (US) 65

Cellectar, LLC. (US) 65

Cell Therapeutics, Inc. (US) 65

Covidien Imaging Solutions (US) 65

Cytogen Corporation (US) 66

Draximage Inc (Canada) 66

GE Healthcare Limited (UK) 66

GlaxoSmithKline Plc (UK) 66

IBA Molecular North America, Inc. (US) 67

Immunomedics, Inc. (US) 67

Kimberly-Clark, Inc. (US) 67

Lantheus Medical Imaging, Inc (US) 67

MDS Nordion (Canada) 68

Molecular Insight Pharmaceuticals, Inc. (US) 68

Peregrine Pharmaceuticals, Inc. (US) 68

PETNET Pharmaceuticals, Inc. (US) 68

Pharmalucence, Inc. (US) 69

Triad Isotopes, Inc. (US) 69

EXHIBITS

Table 1: Percentage Share Breakdown of Leading Medical

Diagnostics Imaging Manufacturer Value Sales in the World -

2003

Table 2: Percentage Revenue Market Shares of Leading

Radiopharmaceutical Medical Diagnostics Manufacturers in the

World - 2003

Table 3: Percentage Share Breakdown of Radioimmunotherapy

Products Manufacturer Value Sales in the World - 2003

Table 4: Breakdown of Diagnostic Radiopharmaceutical Agents

Procedure Volume by Imaging Procedure in the US - 2009

Table 5: Percentage Share Breakdown of Diagnostic

Radiopharmaceutical Agents in the US - 2012

Table 6: Percentage Share Breakdown of SPECT Myocardial

Perfusion Imaging (MPI) Procedure Volume by Imaging Agent in

the US - 2007

Table 7: Percentage Share Breakdown of Non-Cardiology

Diagnostic Radiopharmaceuticals Agent Manufacturer Value Sales

in the US - 2009

Table 8: Installed Base for SPECT and SPECT/CT Scanners in

Units in the North American Diagnostic Radiopharmaceutical

Market for Years 2008, 2010, 2012 & 2014

Table 9: Breakdown of FDG Procedure Volume by Procedure Type -

2009 (In 000s)

Table 10: US FDG Radiopharmacy Market: Number of Doses, Unit

Cost and Number of Nuclear Pharmacies for the Years 2008 &

2012(P)

Table 11: Percentage Share Breakdown of Leading Diagnostics

Radiopharmaceuticals Agents Manufacturer Value Sales in the US -

2007

Table 12: Percentage Share Breakdown of Leading Cardiology

Diagnostic Radiopharmaceutical Agents Manufacturer Value Sales

in the US - 2007

Table 13: Percentage Share Breakdown of Leading Non-Cardiology

Diagnostic Radiopharmaceutical Agents Manufacturer Value Sales

in the US - 2007

Table 14: Percentage Share Breakdown of Therapeutic

Radiopharmaceuticals Manufacturer Value Sales by Key

Radiotherapeutics in the US - 2007

Table 15: Percentage Share Breakdown of Leading Therapeutic

Radiopharmaceutical Agents Manufacturer Value Sales in the US -

2007

Table 16: Percentage Share Breakdown of Leading FDG

Manufacturers by Number of Cyclotrons Operated in the US -

2007

Table 17: Percentage Share Breakdown of Radiopharmaceutical

Bone Palliation Procedures by Key Radiotherapeutics in the US -

2005

Table 18: Percentage Share Breakdown of Leading Diagnostics

Radiopharmaceuticals Manufacturer Value Sales in the US - 2001

Table 19: Percentage Share Breakdown of Leading Cardiology

Diagnostics Radiopharmaceuticals Manufacturer Value Sales in

the US - 2001

Table 20: Percentage Share Breakdown of Leading Therapeutic

Radiopharmaceuticals Manufacturer Value Sales in the US -

2001

Table 21: Percentage Share Breakdown of Leading

Radiopharmaceuticals Manufacturer Value Sales by Diagnostic

Procedures in the US - 2001

Table 22: Percentage Breakdown of Radiopharmacy Market in the

US - 2005

Table 23: Percentage Share Breakdown of Leading

Radiopharmacies Manufacturer Value Sales in the US - 2001

Table 24: Radiopharmaceuticals Market by Segment in the US:

2007-2015 (Sales in US$ Million)

Table 25: Percentage Breakdown of Radiopharmaceuticals Market

by Segment in the US for the Years 2009 & 2012

Table 26: Percentage Share Breakdown of Diagnostic

Radiopharmaceuticals by Imaging Modalities in Europe - 2008 &

2012

Table 27: Radiopharmaceuticals Market by Region in Europe:

2007-2015 (Sales in US$ Million)

Table 28: Percentage Breakdown of Radiopharmaceuticals Market

by Region in Europe for the Years 2009 & 2012

Table 29: Radiopharmaceuticals Market by Segment in Europe:

2007-2015 (Sales in US$ Million)

Table 30: Percentage Breakdown of Radiopharmaceuticals Market

by Segment in Europe for the Years 2009 & 2012

Table 31: Radiopharmaceuticals Market by Segment in France:

2007-2015 (Sales in US$ Million)

Table 32: Percentage Breakdown of Radiopharmaceuticals Market

by Segment in France for the Years 2009 & 2012

Table 33: Radiopharmaceuticals Market by Segment in Germany:

2007-2015 (Sales in US$ Million)

Table 34: Percentage Breakdown of Radiopharmaceuticals Market

by Segment in Germany for the Years 2009 & 2012

Table 35: Radiopharmaceuticals Market by Segment in Italy:

2007-2015 (Sales in US$ Million)

Table 36: Percentage Breakdown of Radiopharmaceuticals Market

by Segment in Italy for the Years 2009 & 2012

Table 37: Radiopharmaceuticals Market by Segment in the UK:

2007-2015 (Sales in US$ Million)

Table 38: Percentage Breakdown of Radiopharmaceuticals Market

by Segment in the UK for the Years 2009 & 2012

Table 39: Radiopharmaceuticals Market by Segment in Spain:

2007-2015 (Sales in US$ Million)

Table 40: Percentage Breakdown of Radiopharmaceuticals Market

by Segment in Spain for the Years 2009 & 2012

Table 41: Radiopharmaceuticals Market by Segment in Rest of

Europe: 2007-2015 (Sales in US$ Million)

Table 42: Percentage Breakdown of Radiopharmaceuticals Market

by Segment in Rest of Europe for the Years 2009 & 2012

COMPANIES PROFILED

To order this report:

Medical Equipment and Supply Industry: Radiopharmaceuticals - A US and European Market Analysis

More Market Research Report

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Blood Gas and Electrolyte Analyz...
S
Finn, Warnke & Gayton Announces A New Service For ...